Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11309476 | 0.80 | ALDH1A1 (0.36) | LMNAKMT2A | |
| SCHEMBL11423546 | 0.80 | — | — | |
| SCHEMBL11032143 | 0.77 | HCAR2 (0.36) | LMNATDP1 | |
| SCHEMBL9738701 | 0.74 | LMNA (0.33) | LMNAKMT2A | |
| SCHEMBL7178430 | 0.73 | CYP3A4 (0.34) | KMT2ATDP1 | |
| SCHEMBL17166073 | 0.67 | CTSK (0.38) | CTSKLMNAKMT2ATDP1 | |
| SCHEMBL28478206 | 0.66 | KMT2A (0.40) | LMNAKMT2A | |
| SCHEMBL869806 | 0.66 | LMNA (0.40) | LMNAKMT2A | |
| SCHEMBL4249210 | 0.66 | KMT2A (0.40) | LMNAKMT2A | |
| SCHEMBL24591300 | 0.66 | CTSK (0.36) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0053961-B1 | THIOVINYL-3-CEPHALOSPORIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC SANTE (FR) | 1984-10-24 | — | — | EP | claimed |
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-5037834-A | Heterocycylic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0202763-B1 | 5,6-DIFLUORONAPHTHYRIDINES AND 5,6,8-TRIFLUORO-QUINOLINES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | disclosed |
| WO-1989005643-A1 | HETEROCYCLIC-SUBSTITUTED QUINOLINE-CARBOXYLIC ACIDS | PFIZER INC. (US) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP11 | CTSK 766/4885LMNA 3842/4885KMT2A 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.